However, GLP-1 receptor agonist use has also been associated with reduced risk of developing 10 of 13 obesity-associated cancers (gallbladder cancer, meningioma, pancreatic cancer, hepatocellular cancer, ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer, and kidney cancer) in a large multi-institutional analysis of electronic health records, when compared to insulin.8 Here, GLP1R is linked to pancreatic neoplasm.